STAT published a headline reporting that biotech and pharmaceutical companies have begun testing obesity medications in children as young as six years old. The piece is authored by Elaine Chen and dated Sept. 15, 2026. The story is presented as a STAT+ exclusive and appears as part of The Readout’s biotech news coverage.
The publicly accessible portion of the article establishes the central claim in the headline but does not include the substantive, report-level detail on specific trials, sponsors, dosing, study design, safety signals, or preliminary efficacy results. Those elements are part of the STAT+ subscriber content that the preview links to but does not reproduce in the free excerpt.
The previewed article sits within a roundup of biotech developments. Visible items in the free excerpt include:
A note that Legend Biotech appointed Ingrid Zhang as its new CEO, succeeding Ying Huang.
A brief mention that Vera plans to seek full approval for a kidney drug after what the preview describes as strong Phase 3 results; the headline and surrounding navigation indicate additional reporting on that program elsewhere on STAT.
These items provide context for the newsletter-style summary but are separate from the pediatric obesity reporting highlighted in the headline.
The article’s public text supplies the headline, byline (Elaine Chen), publication date (Sept. 15, 2026), and placement within STAT’s biotech coverage. It explicitly indicates the remainder of the reporting is exclusive to STAT+ subscribers. As a result, the following were not available in the free excerpt and therefore cannot be restated here from the source:
The article clearly flags that those substantive elements are part of the full STAT+ story and are not reproduced in the accessible preview.
Because the source excerpt is limited, clinicians and researchers should note the absence of several key categories of information that would be needed to evaluate the clinical and public health implications of pediatric testing of obesity medicines. Specifically, the source does not report:
All of these items were not reported in the publicly available portion of the STAT article and therefore cannot be detailed here.
The headline reflects an important trend warranting close attention: manufacturers are moving obesity drug development into younger age groups. For clinicians and investigators, the following points summarize the cautious takeaways that can be drawn from the previewed source material itself:
The movement of obesity drug trials into younger pediatric age bands raises key clinical questions about long-term safety, developmental effects, and appropriate endpoints in children. The source states the testing is occurring but does not provide evidence or data to evaluate risk–benefit.
Regulatory oversight and robust safety monitoring will be critical in any pediatric program; the preview does not specify regulatory interactions or safeguards being implemented by sponsors.
Because the full reporting is behind a STAT+ paywall, readers seeking trial names, protocols, or data will need to access the subscriber content or primary company and regulator disclosures for comprehensive information.
STAT’s headline and subscriber-note indicate that biotech companies are initiating testing of obesity medications in children as young as six, but the publicly available excerpt contains no trial-level or outcome data. The full article is a STAT+ exclusive; detailed clinical, safety, and regulatory information was not reported in the free portion of the source and therefore could not be summarized here.